DAWN (Day One Biopharmaceuticals) Research & Development : $227.1 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Day One Biopharmaceuticals's Research & Development for the three months ended in Mar. 2025 was $39.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was $227.1 Mil.

Day One Biopharmaceuticals Research & Development Historical Data

The historical data trend for Day One Biopharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals Research & Development Chart

Day One Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

9.10

43.58

85.62

130.52

227.70

Day One Biopharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Research & Development	Get a 7-Day Free Trial															40.21	92.11	33.56	61.82	39.62

Day One Biopharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $227.1 Mil.

Day One Biopharmaceuticals (NAS:DAWN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Day One Biopharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Day One Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005

Website

https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Executives

York Charles N Ii	officer: COO, CFO and Secretary	901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Jeremy Bender	director, officer: Chief Executive Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Samuel C. Blackman	officer: Chief Medical Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Ai Day 1 Llc	10 percent owner	40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant	director	2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p.	10 percent owner	2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone	director	395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc.	10 percent owner	ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc.	10 percent owner	9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080